Details

Autor(en) / Beteiligte

• Smadja, David M
• Susen, Sophie
• Rauch, Antoine
• Cholley, Bernard
• Latrémouille, Christian
• Duveau, Daniel
• Zilberstein, Luca
• Méléard, Denis
• Boughenou, Marie-Fazia
• Belle, Eric Van
• Gaussem, Pascale
• Capel, Antoine
• Jansen, Piet
• Carpentier, Alain

Titel

Carmat Bioprosthetic Total Artificial Heart is Associated With An Early Hemostatic Recovery and No Acquired Willebrand Syndrome in Calves

Ist Teil von

• Journal of cardiothoracic and vascular anesthesia, 2017

Erscheinungsjahr

2017

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Objectives To determine haemostasis perturbations, including von Willebrand factor multimers, after implantation of a new bioprosthetic and pulsatile total artificial heart (TAH) Design Preclinical study Setting Single-center Biosurgical Research Laboratory Participants Female Charolais calves, 2-6 months of age and weighing 102-122 kg Interventions Surgical implantation of TAH through a mid-sternotomy Measurements and Main Results 4/12 calves had a support duration of several days (4, 4, 8 and 10 days) allowing us exploring early steps of haemostasis parameters, including Prothrombin Time (PT), coagulation factor levels (II, V, VII+X and fibrinogen) and platelet count. Multimeric analysis of von Willebrand factor (VWF) was performed to detect a potential loss of high molecular weight (HMW)-multimers, as previously described for continuous flow rotary blood pumps. Despite the absence of anticoagulant treatment given in the postoperative phase, no signs of coagulation activation were detected. Indeed, after an immediate post-surgery decrease of PT, platelet count and coagulation factor levels, most parameters returned to baseline values. HMW-multimers of VWF remained stable either after initiation or during days of support. Conclusions Coagulation parameters and platelet count recovery in post-operative phase of Carmat TAH implantation in calves, in the absence of anticoagulant treatment, and associated with the absence of decrease in HMW-multimers of VWF is in line with an early haemocompatibility that is currently being validated in human clinical studies.